The U.S. Food and Drug Administration approved Gilead Company Kite’s Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
Retrospective Study on Real-World Treatment Patterns and Outcomes of Acthar Gel in Patients with Refractory Rheumatoid Arthritis Published in Drugs in Context
Autoimmune Diseases, Drugs in Context, NSAIDs, Peer-Reviewed Analysis, Refractory rheumatoid arthritis (RA), Standard of care drugs, TherapeuticsGlobal biopharmaceutical company Mallinckrodt plc announced the publication of findings from a retrospective medical records study assessing the real-world utilization and outcomes of Acthar Gel (repository corticotropin injection) in patients with refractory rheumatoid arthritis (RA) that did not adequately respond to standard-of-care therapies.
The U.S. Food and Drug Administration approved Aurinia Pharmaceuticals Inc.’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis.
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every […]
Johnson & Johnson’s Janssen Pharmaceutical made a strategic call to halt development of pimodivir, an antiviral treatment for influenza A.
AstraZeneca reported that high-level data analysis from the company’s Phase III CASPIAN trial demonstrated that Imfinzi (durvalumab) in combination with standard-of-care chemotherapies confirmed a clinically meaningful and sustained overall survival benefit in patients with extensive-stage small cell lung cancer treated in the first-line setting.
Bristol-Myers Squibb released pooled efficacy and safety results from the Phase III CheckMate -017 and CheckMate -057 trials in patients with previously treated advanced NSCLC.
New results from the NURTURE study demonstrate that pre-symptomatic infants treated with Spinraza are achieving motor milestones that are unprecedented in the natural history of the disease.